Related Experiment Video
Updated: Jun 1, 2026

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model
Published on: April 6, 2021
Design and validation of revised medication assessment tool for community-acquired Pneumonia: rMAT-CAP
Sahar Elnajjar1,2, Sabariah Noor Harun3, Semira Beshir4
1Universiti Sains Malaysia, Gelugor, Malaysia. dr.sahar@dmu.ae.
Background:
Evaluating therapeutic appropriateness is a cornerstone of antimicrobial stewardship. The original Medication Assessment Tool for Community-Acquired Pneumonia (MAT-CAP), developed in Norway, requires adaptation to account for evolving IDSA/ATS recommendations and region-specific antimicrobial resistance patterns in the UAE. To revise, adapt, and validate a Medication Assessment Tool for Community-Acquired Pneumonia (rMAT-CAP), adapted to the UAE healthcare context.
Methods:
A methodological study was conducted in three phases: (1) systematic revision of MAT-CAP indicators in accordance with 2019 IDSA/ATS guidelines and UAE resistance data; (2) content validation through a multidisciplinary Delphi panel of 10 experts; and (3) psychometric validation using inter-rater reliability and criterion validity assessments based on 30 anonymized CAP cases.
Results:
The rMAT-CAP comprised 13 explicit, guideline-aligned criteria covering empirical therapy, microbiological diagnostics, dose adjustment, IV-to-oral switch, and treatment duration. Content validity indices were excellent (mean I-CVI = 0.95; S-CVI/Ave = 0.95). Inter-rater reliability demonstrated almost perfect agreement for the drug domain (κ = 0.87; absolute agreement 90.0%, 95% CI: 73.5-97.9%), substantial agreement for the dose domain (κ = 0.64; absolute agreement 73.3%, 95% CI: 54.1-86.6%), and moderate agreement for the duration domain (κ = 0.45; absolute agreement 80.0%, 95% CI: 61.4-91.1%). Criterion validity showed strong diagnostic performance: sensitivity 100% (95% CI: 83.9-100%), specificity 62.5% (95% CI: 30.6-86.3%), PPV 88.0% (95% CI: 69.0-96.7%), NPV 100% (95% CI: 56.6-100%), and overall accuracy 90.0% (95% CI: 73.5-97.9%).
Conclusion:
The rMAT-CAP is a valid, reliable, and contextually relevant tool for evaluating therapeutic appropriateness in CAP management. Its structured approach supports antimicrobial stewardship initiatives and facilitates standardized audit and feedback in UAE hospitals.
Trial Registration:
Clinical trial number: not applicable.
Related Concept Videos
Pneumonia III: Complications and Assessment
Dosage Regimens: Designs and Approaches
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Asthma-IV: Nursing Management
First, in...